Gregory Rau
Medical · New Haven, CTNPI 1528006038
Payments from drug & device makers
Across 1,009 payments — averaging $209.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$60K
- AbbVie$59K
- Amgen$38K
- LEO Pharma Inc.$28K
- Pfizer$15K
- Galderma Laboratories, L.p.$6K
- plus $6K from 20 others
What the payments were for
- Consulting fees$10,2455%
- Speaking & faculty fees$168,26780%
- Travel & lodging$16,5018%
- Food & beverage$16,2498%
- Education$280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 159 | $59,824 |
| AbbVie | 207 | $58,569 |
| Amgen | 113 | $37,516 |
| LEO Pharma Inc. | 83 | $28,037 |
| Pfizer | 105 | $15,354 |
| Galderma Laboratories, L.p. | 31 | $5,610 |
| E.r. Squibb & Sons, L.L.C. | 26 | $700 |
| Journey Medical Corporation | 12 | $591 |
| Johnson & Johnson | 30 | $578 |
| Sanofi | 22 | $563 |
| Sun Pharmaceutical Industries Inc. | 25 | $466 |
| Regeneron Healthcare Solutions, Inc. | 21 | $457 |
| UCB, Inc. | 29 | $456 |
| Incyte Corporation | 21 | $409 |
| Dermavant Sciences, Inc. | 23 | $385 |
| Novartis | 21 | $367 |
| Almirall LLC | 20 | $363 |
| Arcutis Biotherapeutics, Inc. | 19 | $254 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 10 | $190 |
| Organon | 11 | $183 |
| Mayne Pharma Commercial LLC | 7 | $120 |
| Boehringer Ingelheim | 5 | $118 |
| EPI Health, LLC | 4 | $83 |
| Verrica Pharmaceuticals Inc. | 2 | $43 |
| Botanix SB Inc | 2 | $38 |
| VYNE Pharmaceuticals Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$211,289 in reported general payments places this provider in the 95th percentile of 592 medical providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 17 | $197,321 |
| OtezlaApremilast | 25 | $122,334 |
| Dupixent PenDupilumab | 22 | $97,098 |
| Dupixent SyringeDupilumab | 14 | $61,809 |
| Fluorouracil | 100 | $6,814 |
| Doxycycline Hyclate | 83 | $2,219 |
| Metronidazole | 42 | $2,065 |
| Ketoconazole | 111 | $2,012 |
| Clobetasol Propionate | 43 | $1,875 |
| Clindamycin Phosphate | 37 | $1,564 |
| Triamcinolone Acetonide | 137 | $1,555 |
| Tretinoin | 12 | $1,257 |
| Minocycline Hcl | 25 | $1,230 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 44 | $768 |
| Fluocinonide | 30 | $767 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $37,516 | $122,33425 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 592 medical providers in Connecticut.
Other medical in New Haven
- Ryan DonovanNew Haven$75K
- Audrey LastraNew Haven$13K
- Melissa FairbairnNew Haven$11K
- Kyla RedwoodNew Haven$9K
- Anna RodonskiNew Haven$7K
- Michael SchultzNew Haven$5K
- Breana BrehmNew Haven$5K
- Andrew TurczakNew Haven$5K
- Shilpa DesaiStamford$215K
- John JasinskiNorwalk$185K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.